Specialty Pharmacy

Ublituximab may provide a clinical benefit for patients with multiple sclerosis via lower doses and faster infusion times than current therapies.

Top news of the day from across the health care industry.

Approximately 1.7 million insured US patients are burdened with moderate to severe plaque psoriasis.

The CDC urges health care providers to implement its recommendations and to regularly review their facility infection data, among other intervention methods.

If approved, fedratinib would be the second FDA-approved treatment for myelofibrosis.

There are currently no approved therapies for the prevention of episodic cluster headaches.

Researchers have made progress in understanding why Hispanic children are disproportionately affected by acute lymphoblastic leukemia.

Top news of the day from across the health care landscape.

Biologic dupilumab plus non-cosmetic topical moisturizer associated with significantly improved symptoms and health-related quality of life in particular patients with atopic dermatitis.

Specialty pharmacies and their patients now require technology systems that are more sophisticated in nature than the basic functions used in the past.

First of its kind study suggests commonalities for humans, dogs, and horses with melanoma.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the rapidly changing oncology market and what to look for in the drug pipeline.

There are financial implications and a significant commitment of time, effort, and energy to implement a health system specialty pharmacy.

Top news of the day from across the health care landscape.

Tildrakizumab was approved by the FDA as a subcutaneous therapy for patients with moderate-to-severe psoriasis.

The report analyzed cost and utilization trends across health care services among patients with employer-sponsored insurance.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more.

Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Approved by the FDA in July 2018, Perseris is the first once-monthly, subcutaneous risperidone-containing, long-acting injectable available in the United States.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

Continued consumption of peanuts was associated with positive quality of life and perceptions of safety following immunotherapy treatment for peanut allergy.

The controlled injection offers patients with plaque psoriasis the ease of self-injection.

The findings reinforce the effectiveness of the HPV vaccine in preventing cervical cancer.

Top news of the day from across the health care landscape.

In a real-world setting, long-term outcomes were more favorable following early intensive therapy when compared with first-line moderate-efficacy diseased modifying therapy.

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.